52 assets on TL1A, three of them in Phase 3.
Most advanced at the centre. Hover for asset details; click or tap a program to keep its details open.
Asset records
Developer, originator and indication labels from the captured dataset. Click any row to open the full spreadsheet, including trials and deals.
How advanced are TL1A drugs in each disease?
Phase 1Phase 2Phase 3
| Disease label | Phase 1 | Phase 2 | Phase 3 | Total drugs | Drugs by highest phase |
|---|---|---|---|---|---|
| ulcerative colitis (UC) | 2 | 5 | 3 | 10 | 10 drugs |
| autoimmune colitis | 2 | 2 | 3 | 7 | 7 drugs |
| Crohn's disease | 1 | 2 | 3 | 6 | 6 drugs |
| hidradenitis suppurativa (HS) | — | 1 | 1 | 2 | 2 drugs |
| Immune disorder | — | — | 1 | 1 | 1 drugs |
| inflammatory bowel disease (IBD) | 7 | 1 | — | 8 | 8 drugs |
| rheumatoid arthritis (RA) | — | 4 | — | 4 | 4 drugs |
| axial spondyloarthritis (axSpA) | — | 3 | — | 3 | 3 drugs |
| psoriatic arthritis (PsA) | — | 3 | — | 3 | 3 drugs |
| asthma | 1 | 1 | — | 2 | 2 drugs |
| ankylosing spondylitis (AS) | — | 1 | — | 1 | 1 drugs |
| atopic dermatitis (AD) | — | 1 | — | 1 | 1 drugs |
| interstitial lung disease (ILD) | — | 1 | — | 1 | 1 drugs |
| pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) | — | 1 | — | 1 | 1 drugs |
| systemic sclerosis (SSc) | — | 1 | — | 1 | 1 drugs |
| systemic sclerosis-associated interstitial lung disease (SSc-ILD) | — | 1 | — | 1 | 1 drugs |
| Unspecified | 6 | — | — | 6 | 6 drugs |
| chronic obstructive pulmonary disease (COPD) | 1 | — | — | 1 | 1 drugs |
| metabolic dysfunction-associated steatohepatitis (MASH) | 1 | — | — | 1 | 1 drugs |
| solid tumor | 1 | — | — | 1 | 1 drugs |
Each drug is counted once per disease, at its highest recorded trial phase for that disease across all captured statuses. Drug names are matched to the 52-asset TL1A cohort, ignoring case; unmatched names are excluded and aliases are not independently resolved. Repeat registry entries do not add drugs. A drug can appear in more than one disease row. Disease labels remain as recorded, without merging synonyms. Based on the original 162-trial capture; phase does not imply approval or efficacy.
Explore the underlying assets and trials in the spreadsheet →Market dynamics
The market is accelerating, and 2026 will set the record. Trial starts went 10 → 29 → 54 across 2022–2025. At 44 starts by day 245, 2026 projects to about 66.
Deal-making tells the same story but earlier. Of 29 genuine transactions on this target, the cluster sits in 2022–23 — Pfizer/Roivant, Merck/Prometheus, Roche/Telavant — the years the three Phase 3 assets changed hands. Activity then thinned to 3 and 2 deals in 2024 and 2025, and has picked back up to 5 already in 2026, led by Boehringer Ingelheim paying €1.058bn for Simcere's preclinical SIM0709.
That is the pattern to read: the deals came first and bought the clinical assets, the trials followed, and the 2026 deal revival is aimed at the preclinical ring rather than the centre.
Phase 3 ownership history
Every Phase 3 asset on this target was acquired, and two of the three changed hands twice.
The pattern is consistent: originate somewhere small, prove it, sell it. Tulisokibart is the clearest case — it left Cedars-Sinai, an academic medical centre, on a 2017 licence, and Merck paid for the whole of Prometheus six years later to get it. Afimkibart took the other common route, spun out of Pfizer into a purpose-built vehicle with Roivant, then sold on to Roche eleven months later.
Only duvakitug moved in a single step, and even that is a co-development rather than an outright sale — Teva kept a share.
Companies with Phase 3 asset history
Eight companies hold three assets.
| Asset | Companies attached |
|---|---|
| duvakitug | Teva, Sanofi |
| tulisokibart | Prometheus Biosciences, Merck |
| afimkibart | Pfizer, Roivant, Telavant, Roche |
That is the chain of custody from the previous answer, arriving as a count. Nobody is dropped when an asset changes hands, so the developer list preserves the whole history — and Prometheus and Telavant both come back marked private, not because they are small, but because being acquired removed their listing.
Afimkibart carries four because it moved twice: out of Pfizer into a purpose-built vehicle, then on to Roche. The count is the transaction history in disguise.